08
2025-01
"Top Ten Systematic Anti-Aging Solutions" newly released
San Yi Changsheng launched the new "Top Ten Systematic Anti-Aging Solutions," covering multiple systems including cardiovascular, nervous, immune, metabolic, and skeletal systems. Through personalized health assessments and targeted interventions, the company provides comprehensive health management services to help achieve biological age reversal and extend healthy life expectancy.
30
2023-12
TRIOLOGY LONGEVITY Medical Group Shanghai Flagship Changsheng Medical Center grandly opens
San Yi Changsheng officially launched its flagship longevity medical center in Shanghai, providing high-end, personalized longevity and regenerative medicine services for domestic high-net-worth individuals. The center integrates health assessment, anti-aging interventions, and aesthetic management, incorporating cutting-edge international technologies and premium medical services, aiming to lead a new era in the field of longevity medicine in China.
16
2024-10
"Global Longevity and Regenerative Medicine Forum" successfully held
The "Global Longevity and Regenerative Medicine Forum" hosted by San Yi Changsheng was successfully held in Beijing, attracting scientists, Nobel laureates, and representatives from international top-tier companies from universities such as Oxford and Harvard. The forum focused on the application of gene editing, cellular reprogramming, and glyco-life clock technologies in longevity medicine, providing new ideas for industry innovation and development.
09
2024-05
San Yi Changsheng signed a cooperation agreement with a renowned British life science company to jointly develop "glyco-life clock" technology, offering ultra-precise biological age assessment and disease prediction services to customers. This cooperation further consolidates San Yi Changsheng's global leadership position in the field of longevity medicine.
21
2025-03
Global cell therapy market grows rapidly
According to market research company forecasts, the cell therapy market will reach $45 billion by 2025. Induced pluripotent stem cells (iPSC) and exosome technology have become core growth drivers, with increasing demand for applications in tissue repair and anti-aging fields.
10
2024-08
Strategic cooperation with Saudi Hevolution Fund
San Yi Changsheng and Saudi Hevolution Fund officially signed a cooperation agreement to jointly promote the research and development and industrialization of longevity medicine and regenerative medicine fields. This cooperation will help San Yi Changsheng accelerate its international layout and promote the application of more breakthrough technologies.